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Abstract
Chromatin structure is an important factor in the functional coupling between transcription and mRNA processing, not only
by regulating alternative splicing events, but also by contributing to exon recognition during constitutive splicing. We
observed that depolarization of neuroblastoma cell membrane potential, which triggers general histone acetylation and
regulates alternative splicing, causes a concentration of SR proteins in nuclear speckles. This prompted us to analyze the
effect of chromatin structure on splicing factor distribution and dynamics. Here, we show that induction of histone hyper-
acetylation results in the accumulation in speckles of multiple splicing factors in different cell types. In addition, a similar
effect is observed after depletion of the heterochromatic protein HP1a, associated with repressive chromatin. We used
advanced imaging approaches to analyze in detail both the structural organization of the speckle compartment and nuclear
distribution of splicing factors, as well as studying direct interactions between splicing factors and their association with
chromatin in vivo. The results support a model where perturbation of normal chromatin structure decreases the recruitment
efficiency of splicing factors to nascent RNAs, thus causing their accumulation in speckles, which buffer the amount of free
molecules in the nucleoplasm. To test this, we analyzed the recruitment of the general splicing factor U2AF65 to nascent
RNAs by iCLIP technique, as a way to monitor early spliceosome assembly. We demonstrate that indeed histone hyper-
acetylation decreases recruitment of U2AF65 to bulk 39 splice sites, coincident with the change in its localization. In
addition, prior to the maximum accumulation in speckles, ,20% of genes already show a tendency to decreased binding,
while U2AF65 seems to increase its binding to the speckle-located ncRNA MALAT1. All together, the combined imaging and
biochemical approaches support a model where chromatin structure is essential for efficient co-transcriptional recruitment
of general and regulatory splicing factors to pre-mRNA.
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Introduction
Several molecular events related to the flow of the genetic
information occur in the eukaryotic nucleus. These events depend
on the interplay between proteins and nucleic acids that do not act
in isolation from other molecules, but generally associate in large
complexes that harbor many molecular functions. In this way
distinct steps in nuclear processes can be coupled with each other,
thereby increasing efficiency. A relevant example is the coupling
between the transcription of genes to form nascent pre-mRNA and
the simultaneous processing of these nascent transcripts into
mature mRNA [1,2,3,4].
All steps of pre-mRNA processing, including capping, splicing
and cleavage/poly-adenylation, are known to occur co-transcrip-
tionally [5,6], although to a different degree depending on the
gene. In the case of splicing, organisms as divergent as mammals
and yeasts show splicing factor recruitment as soon as their
binding sites in the pre-mRNA have been transcribed [7,8,9].
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Such co-transcriptional RNA processing is, however, not strict,
especially considering that the sequence heterogeneity of splice
sites found in mammals implies a high variability of recruitment
efficiencies. The presence of splice sites whose sequences fall apart
from the consensus or are partially obstructed by RNA secondary
structures can allow alternative splicing events [10,11]. However,
many constitutive exons also have seemingly weak splice sites,
implying that other factors are needed for their efficient definition.
These extra factors that participate in both constitutive and
alternative splicing are typically auxiliary proteins (trans acting
factors), such as serine-arginine rich (SR) proteins that bind to
sequences in the pre-mRNA (cis elements known as splicing
enhancers or splicing silencers) [12,13,14].
Nuclear architecture is another important factor contributing to
the efficiency and specificity of nuclear functions. The nucleus is
not a homogenous compartment where molecules diffuse freely,
but is rather organized into distinct nuclear compartments [15,16].
This compartmentalization helps to separate molecular functions
within the nucleus, even when these different functions may share
molecular actors. It also contributes to reactions efficiency by
increasing the local concentration of important components. One
example of sub-nuclear compartments in mammalian cells is the
interchromatin granule compartment, usually called nuclear
speckles or interchromatin granule clusters [17]. These nuclear
bodies, normally revealed by immunostaining against the SR
protein SRSF2 (previously known as SC35), localize in chromatin-
free regions and are enriched in several splicing factors involved in
constitutive and alternative splicing. The fact that inhibiting either
transcription [18,19], or pre-mRNA splicing [20] leads to an
accumulation of splicing factors in speckles strongly argues that
this compartment works as a storage/recycling station rather than
as a place where splicing and transcription actually take place.
However, active genes are often found at the periphery of speckles
[21,22]. This suggests that accumulation in these granules can
assist recruitment more efficiently than relying on passive diffusion
throughout the entire nucleoplasm. Consistent with this notion,
splicing factors move from speckles to transcription sites upon gene
activation [19]. How splicing factors are efficiently recruited to the
splice sites to assemble the spliceosome is still a matter of debate, as
is what governs their partitioning between speckle-localized, free
and splicing-committed proteins. A common feature of the nuclear
dynamic assembly of macromolecular complexes seems to be
seeding by RNA molecules, such as the nascent pre-mRNA in the
case of the spliceosome and nuclear-retained noncoding RNAs
such as NEAT1 for paraspeckles [23,24]. Speckles contain the
ncRNA MALAT1, which modulates the localization of several
splicing factors, although it seems not to be necessary for the
speckle structure to form [25,26].
Chromatin is now thought to be another important player in the
efficient co-transcriptional recognition of splice sites [27,28,29,30].
Different lines of evidence support an important role of chromatin
structure in the coupling between transcription and splicing in
mammalian cells. First, experiments using viral systems, reporter
plasmid minigenes and endogenous genes have shown that
compaction of chromatin is correlated with more frequent
inclusion of alternative splicing events [31,32,33,34,35]. Second,
some histone tail modifications can assist the recruitment of
general and regulatory splicing factors to nascent transcripts
through adaptor proteins, hence increasing spliceosome assembly
and/or regulating alternative splicing patterns [36,37]. Third,
several reports have determined that nucleosomes are preferen-
tially positioned over exons with respect to introns
[38,39,40,41,42], and this positioning seems to be higher for
exons with weak splice sites and exons flanked by large introns
[39,42], suggesting a selective pressure which may act to ensure
recognition of difficult exons in the large intron environment of
many mammalian genes. Despite this accumulated evidence on
the influence of chromatin on splicing, no study assessing the
relevance of chromatin structure on the general function of
splicing factors has been conducted so far.
Here, we report that relaxation of chromatin structure,
promoted by different treatments in several mammalian cell lines,
consistently results in depletion of pre-mRNA splicing factors from
nucleoplasm and accumulation in nuclear speckles. We demon-
strate that this nuclear redistribution is due to general impairment
of splicing function and not caused by global transcription
inhibition or post-translational modification of the splicing factors.
Based on the fact that chromatin relaxation does not affect
dynamics of splicing factors, we propose a model describing the
relationship between the subnuclear organization of splicing
factors and chromatin structure. According to this model, the
perturbation of chromatin structure impairs the recruitment of
splicing factors to nascent RNAs. We tested this hypothesis by
assessing early spliceosome recruitment through U2AF65 iCLIP
analysis, which confirms the reduced recruitment and shows that
splicing factors are redirected to low affinity binding sites present
in abundant ncRNAs such as speckles-located MALAT1 and
paraspeckles-located NEAT1.
Results and Discussion
Relaxation of Chromatin Structure causes Accumulation
of Splicing Factors in Nuclear Speckles
In a previous report [35] we showed that treatment of N2a
murine neuroblastoma cells with high extracellular potassium
concentration promotes histone H3 lysine 9 acetylation in an
intragenic region of the NCAM gene, consequently affecting
alternative splicing of exon 18. This effect can be mimicked by
treatment with the histone deacetylases inhibitor trichostatin A
(TSA). As depolarization treatment also causes a general increase
in histone H3 and H4 acetylation [35], we hypothesized that its
effect on splicing could be more general than the modulation of
this particular event. Since we wanted to analyze splicing
mechanisms not biased to any particular gene or exon, we
monitored the distribution of two SR proteins that participate in
alternative and constitutive splicing: SRSF2 and SRSF1. N2a cells
transiently expressing the fluorescent fusion proteins EGFP-
SRSF2 or EGFP-SRSF1 and treated for 6 hours with either high
KCl concentrations (DEPOL) or TSA, showed an increase in the
accumulation of the tagged splicing factors in enlarged speckles in
comparison to control cells (Fig. 1A, arrowheads). To quantify this
accumulation, we measured the fluorescence intensity across a line
in representative cell nuclei. The resulting profiles showed that,
after depolarization or TSA treatment, EGFP-SRSF2 signal had
higher and wider peaks corresponding to the enlarged speckles
(Fig. 1B). Similar profiles were observed for EGFP-SRSF1 (not
shown). As a control, cells were co-transfected with a plasmid
encoding mCherry-H2B histone, which showed no change in the
overall chromatin localization (Fig. 1B). The only apparent change
is a more pronounced H2B valley coincident with SR protein
peaks, supporting the conclusion that the splicing factors are
accumulated in interchromatin granules. To have a more objective
evidence of speckle enlargement upon these treatments, we
quantified the speckles-associated signal of EGFP-SRSF2 and
EGFP-SRSF1 in several individual cells (Fig. 1C). Depolarization
and TSA treatment induced a similar significant increase in the
signal of both splicing factors in speckles compared to control N2a
cells. Altogether, we showed that an extracellular signal known to
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trigger histone acetylation and a drug that causes increased
acetylation by inhibiting deacetylases activity have a similar effect
on the nuclear distribution of these SR proteins, by promoting a
conspicuous and quantitative concentration in nuclear speckles.
To investigate the generality of this phenomenon, we transiently
transfected human cells of non-neural origin with different splicing
factors fused to fluorescent proteins. We analyzed the nuclear
distribution of three different SR proteins (SRSF2, SRSF1 and
SRSF3, the latter previously known as SRp20) and three
constitutive splicing factors (U1 70K, U1A and U2AF65) in HeLa
cells. All six splicing factors accumulated in speckles after
treatment with TSA for 6 hours (Fig. 2A, arrowheads, and Fig.
S1), suggesting that the treatment affects a general step in the
splicing process rather than the behavior of specific proteins.
Since TSA could affect the acetylation status of non-histone
proteins, a possible explanation was that splicing factors were
hyper-acetylated after the treatment and this post-translational
modification could explain the observed stronger localization in
speckles. In fact, acetylation of SR proteins was already described
for SRSF2 [43]. We monitored whether TSA affected the
acetylation status of SRSF2 and SRSF1 by transfecting HEK-
293T cells with plasmids encoding T7-tagged proteins, immuno-
precipitating them and performing Western blot analysis with an
antibody that recognizes acetylated lysines (Fig. 2B). To verify that
TSA was effective in increasing acetylation levels and to check if
the acetyl-Lys antibody worked properly, we purified histones
from cells either untreated or treated with TSA. As expected, an
increase in the antibody signal was detected in histone extracts
Figure 1. Membrane potential depolarization and TSA treatment of neuroblastoma cells cause splicing factors accumulation in
speckles. (A) N2a cells were transiently transfected with plasmids encoding SRSF2 or SRSF1 splicing factors fused to EGFP, along with a plasmid
encoding histone H3 fused to mCherry. After one day, cells were either treated for 6 hours with 0.2 ng/ml TSA (TSA), 60 mM KCl (DEPOL) or left
untreated (CONTROL). Enlarged nuclear speckles in N2a cells containing the splicing factors in DEPOL or TSA-treated cells are marked by yellow
arrowheads. Scale bars, 5 mm. (B) Analysis of intensity profile of EGFP-SRSF2 and mCherry-H2B signals across a line (yellow dotted lines) for a
representative cell for each experimental condition. SRSF2 profile shows higher and wider peaks in DEPOL and TSA cells, corresponding to
enlargement of nuclear speckles. No intensity changes are observed for mCherry-H2B profiles. The drop in mCherry-H2B signal at the SRSF2 peaks is
typical of inter-chromatin granules. Scale bars, 5 mm. (C) Statistical analysis of splicing factor enrichment in speckles. Signal of EGFP-SRSF2 (top) and
EGFP-SRSF1 (bottom) in speckles increases both in response to depolarization and TSA treatments. Intensity of splicing factor in all speckles of a focal
plane was calculated for individual cells using automatic threshold and particle analysis (see Materials and Methods). The total integrated density of
speckles particles was normalized by total integrated density of the cell. For EGFP-SRSF2, 10 cells (Control), 8 cells (Depol) and 11 cells (TSA) were
analyzed. For EGFP-SRSF1, 10 cells (Control), 7 cells (Depol) and 10 cells (TSA) were analyzed. * means significant differences between treated and
control cells, using Mann-Whitney U test (p = 0.023 in Depol and 0.0044 in TSA for EGFP-SRSF2; p = 0.036 in Depol and 0.031 in TSA for EGFP-SRSF1).
doi:10.1371/journal.pone.0048084.g001
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from TSA-treated cells (Fig. 2B, lanes 2 vs. 1). In contrast, only a
weak acetyl-Lys signal was detected for T7-SRSF2 and only a
slightly stronger signal for T7-SRSF1 (lanes 5 and 9 vs. 3). More
importantly, no increase in lysine acetylation was detected after
TSA treatment for these SR proteins (Fig. 2B, lane 6 vs. 5 and lane
10 vs. 9). Since acetylation of SRSF2 was reported to result in
degradation by the proteasome [43], we tested if an increase in the
levels of T7-SRSF2 acetylation was revealed after inhibition of
proteasome activity by MG132. No changes in the acetylation
levels of T7-SRSF2 were detected after MG132 treatment, either
in the absence, or presence, of TSA (Fig. 2B, lanes 7–8 vs. 5–6).
From these experiments we concluded that the possibility of a
TSA-triggered accumulation of splicing factors in speckles due to
enhancement of their acetylation levels is unlikely.
As previously mentioned, inhibition of transcription causes the
accumulation of splicing factors in speckles. Although TSA is not
expected to inhibit transcription, a partial effect on de novo RNA
synthesis could in theory cause the observed effect. To test this, we
Figure 2. Histone acetylation affects distribution of several splicing factors involved in constitutive and alternative splicing. (A)
Several splicing factors tested show accumulation in nuclear speckles after a 6-hour TSA treatment of HeLa cells, including many SR proteins (SRSF2,
SRSF1, SRSF3) and proteins of the U1 and U2 complexes (U1 70K, U1A, U2AF65). Top row shows control cells and bottom row shows cells treated with
0.2 ng/ml TSA. Some enlarged nuclear granules containing splicing factors in TSA-treated cells are marked by yellow arrowheads. Scale bars, 5 mm. (B)
TSA treatment affects histone but not splicing factor lysine acetylation. HEK-293T cells were transfected with plasmids coding for the indicated
tagged proteins (lanes 5–10) or not transfected (lanes 1–4). After one day, cells were incubated for 6 hours with or without 1 mM TSA, lysed and either
histones were extracted (lanes 1–2) or proteins immunoprecipitated with antibodies against T7 tag (lanes 3–10). Purified proteins were analyzed by
Western blot using an antibody that recognizes acetylated lysines (aAcLys, upper panels). As loading controls, proteins were also detected with
antibodies against histone H3 or T7 tag (lower panels). In lanes 1 and 2, the two bands for the aAcLys correspond to histones H3 and H4, showing a
dramatic increase of acetylation in both histones upon TSA treatment. In lanes 7 and 8, cells transfected with T7-SRSF2 were treated with the
proteasome inhibitor MG132 (see text). (C) Total transcription is not affected after 6 h-TSA treatment. Global levels of nascent RNA in untreated and
TSA-treated HeLa cells were measured by in vivo 5-FU incorporation and immunostaining with an antibody specific for 5-FU nucleotide. A
representative field for each condition is shown. Brighter spots correspond to ribosomal RNA in nucleoli. Scale bars, 10 mm. Quantification of the 5-FU
signal in individual cells (see Materials and Methods) shows no significant change in transcription in TSA-treated vs. Control cells (n= 15 and 10
respectively). In contrast, treatment with the P-TEFb inhibitor DRB (n= 10 for each condition) and with the general transcription inhibitor actinomycin
D (n= 5 for Control and 6 for ActD) causes a clear decrease in 5-FU incorporation, as expected from transcriptional inhibition.(D) Time course of EYFP-
SRSF3 distribution in HeLa cells treated with 0.2 ng/ml TSA. A representative nucleus is shown. Images were acquired every 30 minutes. Yellow
arrowheads point to a single speckle where accumulation of the tagged-SR protein is observed. Scale bars, 5 mm.
doi:10.1371/journal.pone.0048084.g002
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measured general RNA synthesis levels by pulse-labeling nascent
RNAs with the modified nucleotide 5-fluoruracil (5-FU) and
performing immunofluorescence analysis with an antibody that
recognizes 5-FU (Fig. 2C). The labeling was distributed all over
the nucleus, with some intense foci corresponding to rRNA
synthesis in nucleoli. We quantified the mean fluorescence
intensity in nuclei from control and TSA-treated HeLa cells and
detected no significant differences in the levels of general RNA
synthesis (Fig. 2C, Histone acetylation graph). As a proof that
measure of 5-FU incorporation can detect both general and pol II-
mediated transcriptional inhibition, we performed the same
analysis on HeLa cells treated with drugs that inhibit transcription
through different mechanisms. The nucleotide analog 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) is known
to partially prevent pol II transcription through inhibition of the
elongation factor P-TEFb. In our assay, a 2 h treatment with
25 mg/ml DRB caused a ,40% decrease in 5-FU incorporation
(Fig. 2C, P-TEFb inhibition graph), a magnitude comparable to
nuclear run-on measurements in cells treated with P-TEFb
inhibitors [44]. As expected, a 2 h treatment with 1 mg/ml
actinomycin D (ActD), that affects transcription by all RNA
polymerases, led to an almost complete inhibition (near 90%) of 5-
FU incorporation (Fig. 2C, Transcription inhibition graph),
showing the dynamic range of this assay. Finally, to rule out
potential general effect of TSA on pol II transcriptional
elongation, we performed immunostaining with an antibody
against tri-methylated lysine 36 of histone H3 (H3K36me3), a
hallmark of actively transcribed regions, on HeLa cells. Treatment
with TSA for 2 or 6 hours didn’t reveal any significant alteration of
H3K36me3 pattern (Fig. S1). Also, we didn’t detect consistent
transcription inhibition of individual genes (not shown). In
conclusion, the 5-FU incorporation assay shows no general
inhibition of transcription by the TSA treatment while the
H3K36me3 staining shows no effect on a pol II elongation-
associated mark. These results rule out the possibility that TSA is
exerting its effect through inhibition of transcription.
The lack of any TSA effects on splicing factor acetylation and
general transcription levels argues against indirect effects being
responsible of the observed accumulation of splicing factors in
speckles. Moreover, the fact that accumulation in speckles is
already high 6 hours after TSA addition suggests that TSA starts
exerting its effect immediately and supports a direct effect, rather
than an indirect effect, such as changing the patterns of splicing
regulators or interference with cell cycle progression. To confirm
this, and to make sure that the reorganization occurs within an
individual cell, we performed time-lapse experiments on single
cells expressing fluorescent fusion splicing factors. As seen in
Fig. 2D for EYFP-SRSF3, a gradual increase of speckle
fluorescence intensity (Fig. 2D, arrowhead) with respect to the
nucleoplasm is already evident at short times, reaching a
maximum at around 4 hours.
Analysis of Endogenous Splicing Factor Distribution and
Speckle Structure After Perturbation of Chromatin
Structure
While general transcription is not substantially affected by TSA
treatment, it could enhance the overexpression of exogenous fused
FPs-splicing factors constructs over time. As a consequence, the
excess of splicing factors could cause the impression of concen-
tration in speckles. To verify that overexpression is not responsible
for the observed speckle-accumulation of the splicing factors, we
analyzed the distribution of endogenous SRSF2 by indirect
immunofluorescence in HeLa cells, either untreated, or treated
with TSA (Fig. 3A). TSA-induced accumulation of SRSF2 in
speckles was also seen for the endogenous protein, although the
enlargement of speckles was not as dramatic as the one seen for
some cells in transient transfection experiments. This could be in
part because there is no overexpression of the endogenous protein,
even in the presence of TSA. We quantified the total SRSF2 signal
in single cells and detected no significant difference between
control and TSA-treated cells (Fig. 3B). By plotting the intensity
profiles across a single nucleus, enrichment of endogenous SRSF2
in speckles can be seen as an increase in the height of the intensity
peaks (Fig. S2). Even more clearly than its accumulation in
speckles, depletion of splicing factors from the nucleoplasm in
TSA-treated cells was evident from our experiments with
endogenous SRSF2 (Fig. 3A). To quantify this effect in the cell
population, we measured for each cell the intensity of the
nucleoplasmic fraction and compared the distribution of the
nucleoplasmic/total SRSF2 ratio (referred to as ‘‘nucleoplasmic
fraction’’) in control and TSA-treated cells. As shown in Figure 3C,
cells treated with TSA showed a decrease in the SRSF2
nucleoplasmic fraction.
To study the structural organization of speckles and the nuclear
distribution of SRSF2 at high resolution, we used Structured
Illumination Microscopy (SIM)/OMX technique. TSA-treated
cells showed speckles that were larger, more dense and with better
defined edges than those of control cells (Fig. 3D). In addition,
thanks to the SIM/OMX technology, we found that after TSA
treatment speckles show a particular ordered internal structure
similar to a repetitive tubular-like organization, as compared with
control cells where speckles appear less ordered and structured
(Fig. 3D, see high magnification insets; 3D-reconstruction of
speckles in control and TSA-treated HeLa cells is shown in Movies
S1 and S2, included as supplementary data). Furthermore, while
speckles normally exhibit projections into the nucleoplasm that are
considered as an evidence of recruitment of splicing factors to
active transcription sites [19], the speckles of TSA-treated cells
showed little continuity with the nucleoplasm. Indeed, the
dispersed SRSF2 foci seen in the nucleoplasm and around speckles
in control cells are diminished in TSA-treated cells (Fig. 3D,
insets). In conclusion, TSA treatment causes depletion of
endogenous SRSF2 from the nucleoplasm and results in its
concentration in dense and well-structured speckles, with little
continuity between these two compartments.
TSA treatment causes a massive increase in histone H3 and H4
acetylation (Fig. 2B) and general chromatin relaxation [45]. To
test if the altered distribution of splicing factors can be induced by
other types of chromatin structure perturbation and is not
specifically related to histone acetylation, we analyzed the effect
of knocking down the heterochromatin protein HP1a. This
protein, like its paralog HP1c, is necessary for chromatin-mediated
increase in the inclusion of some alternative exons [32,46]. This
suggests that the chromatin conformation dependent on these
proteins either participates in, or has cross-talk with, the splicing
process. Efficient siRNA knockdown of HP1a in HeLa cells (Fig.
S3 shows HP1a depletion) caused a redistribution of endogenous
SRSF2 similar to that observed with the TSA treatment: depletion
from nucleoplasm and accumulation in speckles (Fig. 3E). Again,
this resulted in higher SRSF2 peaks when intensity profiles across
a line are plotted (Fig. S4A) and in significantly increased SRSF2
signal associated to speckles when analyzing the cells population
(Fig. S4B).
Together, our results indicate that a perturbation of the native
chromatin structure leads to a redistribution of several splicing
factors from the nucleoplasmic pool to speckles. These enlarged
speckles are mostly discontinuous with the nucleoplasm, suggesting
Splicing Factors and Chromatin Structure
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that recruitment of splicing factors from speckles to nascent pre-
mRNA sites might be impaired.
Dynamic Interactions are not Affected by Disruption of
Chromatin Structure
To get further insight into the mechanism of splicing factor
accumulation in speckles, we performed a series of microscopy
experiments to measure changes in different aspects of splicing
factor dynamics. For most of the experiments we used the SR
protein SRSF1 as a model, because of the prior knowledge about
its behavior and the availability of requisite tools. First, we
measured the dynamics of SRSF1 association and diffusion from
speckles by Fluorescence Recovery After Photobleaching (FRAP)
experiments, either in untreated, or in TSA-treated cells (Fig. 4A,
left). Little or no change in the rate of fluorescence recovery in
speckles was observed after TSA treatment, suggesting that the
affinities of the interactions responsible for the localization of this
splicing factor in speckles are not affected. The same was observed
for U2AF65 (Fig. 4A, right). This experiment provides strong
evidence against the possibility that TSA exerts its effect through
changing the interaction properties between splicing factors and
their partners in speckles.
Splicing factors show a slower diffusion rate in the nucleoplasm
than expected for freely diffusing molecules [47,48], suggesting
that they are continuously interacting with many components of
the nucleus, including chromatin (either with DNA or histones),
Figure 3. Analysis of endogenous SRSF2 distribution shows that histone acetylation causes splicing factor depletion from
nucleoplasm. (A) Immunostaining for endogenous SRSF2 in HeLa cells untreated or treated with TSA (0.2 ng/ml, 6 hours). DNA was stained with
DAPI. Visualization of endogenous SRSF2 distribution suggests depletion from nucleoplasm after TSA treatment. Scale bars, 10 mm. (B) Total levels of
endogenous SRSF2 do not change upon TSA treatment. Box plot showing similar distribution of SRSF2/DAPI intensities in individual untreated or
TSA-treated HeLa cells (26 cells of each type). The SRSF2/DAPI ratio is NOT significantly different between CONTROL and TSA cells (Mann-Whitney U
test: p = 0.23; Kolmogov-Smirnov test: p = 0.501). (C) TSA treatment causes depletion of nucleoplasmic SRSF2 fraction. Nucleoplasmic intensity was
calculated in the same cells as (B) (see Materials and Methods). Box plot shows nucleoplasmic/total SRSF2 fractions in CONTROL and TSA cells, which
further supports the observation of SRSF2 depletion from nucleoplasm after TSA treatment. The nucleoplasmic SRSF2 fraction is significantly reduced
in TSA-treated cells compared to control cells (marked by asterisk; Mann-Whitney U test: p= 0.0017; Kolmogov-Smirnov test: p= 0.018). (D) High
resolution imaging analysis of SRSF2 distribution and speckle internal structure in untreated and TSA-treated cells. Control and TSA-treated cells were
fixed, immunostained for SRSF2 and analyzed by SIM/OMX microscopy. Upper panels: a representative cell in each condition is shown, where
depletion of diffuse SRSF2 in nucleoplasm and concentration in speckles is apparent after TSA treatment. Lower panels: enlarged view of an
individual speckle (yellow boxes) from cells in each experimental condition. Scale bars, 5 mm. (E) HP1a knockdown has similar effect than TSA
treatment on endogenous SRSF2 distribution. HeLa cells were transfected with control siRNAs or siRNAs against HP1a. After two days, the cells were
fixed and stained for endogenous SRSF2. Depletion of nucleoplasmic SRSF2 staining and accumulation in speckles is evidenced, similar to what is
seen after TSA treatment (A). Scale bars, 5 mm.
doi:10.1371/journal.pone.0048084.g003
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RNAs and other proteins. Therefore, a likely possibility is that the
splicing factors interactions in the nucleoplasm are weaker after
TSA treatment, increasing the number of free nucleoplasmic
splicing factor molecules and therefore favoring their displacement
to the speckles. Since TSA affects chromatin structure, we measure
direct interaction between splicing factors and chromatin in vivo.
Not much is known about how splicing factors interact directly
with histones, besides one report of a phosphorylation-dependent
interaction of SRSF1 and SRSF3 with histone H3 [49]. Bearing in
mind that these interactions would possibly be weak (but
Figure 4. Splicing factor dynamics suggests that accumulation in speckles is due to inefficient recruitment to pre-mRNA. (A) FRAP
analysis of SRSF1 and U2AF65 splicing factors fused to EYFP show that their kinetics of association to speckles are not modified after TSA treatment.
For this experiment, C33A cells stably expressing the corresponding EYFP-fusion protein were used. Similar results were obtained for other splicing
factors transiently transfected in HeLa cells (not shown). We show a representative cell for each group. The circle shows the speckle area where the
laser pulse was applied, and where fluorescence recovery was measured afterwards. Fluorescence intensity is expressed relative to the fluorescence
prior photobleaching. The length of TSA treatment was 4 h for U2AF65 and 6 h for SRSF1. The curves are averages from 10 to 15 cells. (B) Direct
interaction between splicing factors and histones is detectable but not affected by TSA treatment. Interaction between the mCherry-tagged splicing
factor SRSF1 and the EGFP-tagged histone H2B was analyzed by FLIM-FRET technique. A representative cell expressing both tagged proteins and its
FRET efficiency map is showed. Also, the FRET efficiency map of a representative cell expressing EGFP-H2B and mCherry-C1 empty plasmid is shown
as a control (NO FRET). The pixels histogram shows average FRET efficiency distributions for Control (7 cells) and TSA-treated cells (6 cells). Peaks of
FRET are marked by colored arrowheads, indicating interaction between these two proteins. Nuclear regions associated to these distinct FRET
populations are also marked by colored arrowheads in the E FRET map. (C) Nucleoplasmic interaction between splicing factors is not impaired by TSA
treatment. The interaction between EGFP-U1-70K and mCherry-SRSF1, a known interaction pair [51] was assessed by FLIM-FRET in Control and TSA-
treated cells. Upper panels: control cells, transfected with mCherry instead of mCherry-SRSF1, show no FRET signal in either speckles or nucleoplasm.
Lower panels: FRET efficiency between the two splicing factors is intermediate in nucleoplasm (green) with stronger (red) areas in speckles (marked
with white arrowheads in control cells). (D) Proposed model to explain how relaxation of chromatin structure affects splicing factor distribution.
Nucleoplasmic free splicing factors are in dynamic equilibrium with splicing factors in speckles (a). Free splicing factors can also interact with other
splicing factors independently of splicing (b), these complexes being found both in nucleoplasm and speckles. However, what we call nucleoplasmic
fraction involves also splicing factors briefly interacting with other molecules (such as histones) through abundant low affinity interactions (c) and
splicing factors recruited to RNA and engaged in productive spliceosome assembly (d). For model simplicity, in c we only included interactions with
histones and in d we only depicted co-transcriptional splicing. The red lines and arrows symbolize the proposed system response after TSA treatment:
decreased efficiency in recruitment cause an excess of free splicing factors that is buffered by the speckles compartment.
doi:10.1371/journal.pone.0048084.g004
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nonetheless important for splicing factor distribution because of
the abundance of histones), we used a sensitive method based on
Fo¨rster Resonance Energy Transfer (FRET) by using Fluorescence
Lifetime Imaging Microscopy (FLIM) technique [50] to detect and
spatially map the direct interaction between EGFP-H2B histones
and mCherry-SRSF1 splicing factors. In comparison to control
EFRET cell map (Fig. 4B, EGFP-H2B/mCherry-C1 panel), we
were able to detect a widespread, although weak, direct interaction
between these two proteins, which was not affected by TSA
treatment (Fig. 4B, green signal in the EGFP-H2B/mCherry-
SRS1 EFRET cell map, marked by green arrow in the pixels
histogram; see also Materials and Methods). An additional minor
FRET efficiency population around 6% is detected between
EGFP-H2B and mCherry-SRSF1 (see Fig. 4B, orange signal in the
FRET cell map, marked by orange arrow in the pixels histogram)
that might reflect EGFP-H2B/mCherry-SRSF1 interactions in a
more constraint and tight chromatin environment. The interacting
molecules are distributed through the nucleus but mostly excluded
from speckles (Fig. 4B). This suggests that disruption of low affinity
direct interactions between splicing factors and chromatin is not
the cause of accumulation in speckles after TSA treatment.
As a model of the interaction among different splicing factors we
used the known interacting partners U1 70K and SRSF1. These
two splicing factors interact with each other in the nucleoplasm
and in speckles, and some of the interacting pairs remain even in
the absence of transcription and splicing [51]. We asked whether
this direct interaction between different splicing factors in the
nucleoplasm is diminished as a consequence of the TSA treatment.
FLIM-FRET analysis of this interaction, either in the absence or
presence of TSA, clearly argues against this hypothesis, since no
decrease in FRET efficiency was detected in the nucleoplasm
(Fig. 4C). On the contrary, the only effect observed was an
increase of the red-colored areas in speckles (high-affinity
interactions). Since these high-affinity interactions were already
present in untreated cells (Fig. 4C, middle panels, marked by white
arrowheads), but became more frequent after TSA treatment, this
provided evidence of more interacting pairs formed upon
chromatin perturbation. This is consistent with the accumulation
in speckles seen in the previous experiments.
Model of how the Perturbation of Chromatin Structure
Affects Splicing Factor Distribution
The analysis of splicing factor behavior is complicated because
of the many interactions, complexes and structures where they
seem to be involved. Even a simplified model, as proposed in
Figure 4D, has to take into account several equilibria. First, while a
clear partition exists between the nucleoplasmic and the speckle-
associated splicing factor pools, FRAP analysis shows that these
two compartments are in dynamic equilibrium (marked as a in
Fig. 4D). However, the nucleoplasmic fraction is not homogenous.
Judging from analysis of diffusion by Fluorescence Correlation
Spectroscopy (FCS) and FRAP experiments [47,48], nucleoplas-
mic splicing factors do not diffuse freely, but rather are constantly
engaged in interactions that reduce their effective diffusion rate.
We exemplify these interactions with low affinity direct binding of
splicing factor to histones (b), although it can also involve
interactions with other proteins, with DNA and/or low affinity
and non-productive binding to RNA. In addition, previous reports
have shown the existence of complexes between different splicing
factors that are at least partially splicing-independent [51]. These
complexes exist both in the nucleoplasm and in speckles. We
incorporate this in our model by adding an equilibrium between
unbound nucleoplasmic splicing factors and nucleoplasmic splicing
factors forming complexes (c), and also by assuming that
complexed splicing factors are in equilibrium between nucleo-
plasm and speckles (second pair of arrows in a). We do not
consider here the additional possibility of equilibrium between free
and complexed splicing factors in speckles, but this would not
affect our conclusions. Finally, in addition to free and complexed
splicing factors, the nucleoplasmic pool also includes the splicing-
engaged proteins and the ones that are forming stable complexes
with mature mRNA. For simplicity, we only consider co-
transcriptional recruitment, assuming also that the transcription
machinery participates in the recruitment of splicing factors to
nascent RNA (d).
Based on our observations, we propose that the main cause for
the observed changes in splicing factor distribution upon TSA
treatment and HP1a knockdown is that productive recruitment of
splicing factors to nascent RNAs is impaired by disruption of
normal chromatin structure. We cannot distinguish here between
two likely causes of reduced recruitment efficiency upon chromatin
perturbation: either (a) less pol II pausing in the proximity of splice
sites, or (b) modification of histone marks involved in the
recruitment of splicing factors. Nevertheless, both explanations
imply a participation of the chromatin structure in the splicing
process. Several facts support this notion: 1) HP1a knockdown has
similar effects to TSA treatment, suggesting that the effect is due to
a change in chromatin structure (Fig. 3E) and not specifically to
histone acetylation; 2) the distribution of not just one but several
splicing factors is affected, suggesting a general impairment of the
splicing process (Fig. 2A); 3) the splicing factors themselves are not
acetylated in response to TSA treatment, implying that TSA is not
affecting the proteins but rather a process in which the proteins
take part, such as splicing (Fig. 2B); 4) while projections of speckles
into the nucleoplasm are considered an indication of recruitment
to transcription sites, the high resolution imaging analysis of TSA-
treated cells shows speckle structures with little continuity with the
nucleoplasm (Fig. 3D); 5) no changes in the kinetics of interchange
between speckles and nucleoplasm could be detected by FRAP,
suggesting that splicing factors are not being more strongly bound
to a component of speckles (Fig. 4A); 6) while a decrease in
nucleoplasmic interactions normally engaged by splicing factors
could explain an excess of free protein (that is in turn relocated to
speckles), no decrease was found after TSA treatment for the tested
interactions (Fig. 4B and C).
Since splicing factors engaged in productive splicing are thought
to form stable complexes with the mRNA, in most cases even
being exported from the nucleus [52,53], splicing commitment
represents a drain of splicing factor from the equilibria depicted in
Fig. 4D. Therefore, if a fraction of the splicing factors cease to be
recruited (symbolized by the red inhibition symbol in Fig. 4D), the
excess of free splicing factors will be buffered by the other
compartments. Therefore, it is perfectly consistent that the excess
of splicing factors not recruited for splicing is buffered by the
speckles (this flow of the excess of free splicing factors is symbolized
by the wider arrows in Fig. 4D). Since RNA bound splicing factors
are detected in the nucleoplasmic pool, this model would explain
the observed decrease in nucleoplasmic staining (Fig. 3C). In this
case, we consider that the contribution of the splicing factor
binding sites in chromatin and RNA molecules is minimal, which
would be the case if these interactions have lower affinities than
the ones that keep splicing factors in speckles. This assumption
comes from the fact that the speckle compartment is known to
buffer the excess of splicing factor when inhibiting transcription or
splicing [18,19,20].
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TSA Impairs U2AF65 Recruitment to the 39 Splice Sites of
pre-mRNAs
To test the hypothesis that splicing factor accumulation in
speckles is caused by a reduction in their commitment to splicing,
we decided to measure whether recruitment of a splicing factor to
pre-mRNA is affected by TSA treatment. We chose the U2-
snRNP auxiliary factor protein U2AF65 for technical reasons, but
also because it is a good indicator of early spliceosome assembly.
As an unbiased approach, instead of measuring recruitment to a
particular pre-mRNA, we used individual nucleotide resolution
crosslinking immunoprecipitation (iCLIP) technique followed by
high-throughput sequencing [54] to measure the recruitment of
U2AF65 to bulk cellular pre-mRNAs. In this way we could
monitor global spliceosome assembly efficiency, which can be
affected by changes in the recruitment of many splicing factors,
integrating the changes of multiple proteins in one output.
Based on the time course of splicing accumulation after TSA
treatment (Fig. 2D), we performed two different time points for the
iCLIP experiment: 2 hours, when the accumulation of splicing
factor in speckles is starting, and 6 hours, when the accumulation
of splicing factors in speckles is at its maximum. As shown in
Figure 5A, while no accumulation U2AF65 is detected in any
region of exon-intron junctions (E-I, top), a peak near the end of
introns. i.e. at intron-exon junctions (I-E, bottom) is present in the
three different conditions, consistent with the fact that U2AF65
binds to the poly-pyrimidine tract upstream of 39splice sites (39ss).
This also provides evidence for the specificity of the iCLIP
experiment. A comparison of the types of RNA sequences
represented in the three libraries showed that there are no major
differences between the Control and the TSA samples in the
distribution of U2AF65 binding among types of RNA sequence
(Fig. S5A). When we analyzed counts on specific RNA biotypes,
the only category where a clear increase is seen upon TSA
treatment is the long intergenic non-coding RNAs (Fig. S5B,
‘‘lincRNA’’, marked with an orange box).
When comparing the heights of the 39ss peaks among the three
samples (Control, TSA 2 h and TSA 6 h) a decrease of around
17% in the height of the 39 splice site peak is detected for TSA 6 h,
but not for TSA 2 h (Fig. 5A bottom, green line), showing that
recruitment of U2AF65 to 39ss is diminished after 6 h of TSA
treatment. This result supports our model, since 6 hours after TSA
addition splicing factor depletion from the nucleoplasm is evident
from the microscopy experiments.
Since our model indicates that failure of splicing factor
recruitment is the cause of the accumulation, a partial reduction
in U2AF65 binding to 39 splice sites is expected at the 2 h point.
This could not be evident in the bulk of pre-mRNA bound
U2AF65 (Fig. 5A), but we assume that some genes and exons
would be more sensitive to the TSA effect than others. We
therefore analyzed the proportion of genes where U2AF65 binding
to intron-exon junctions was affected by the 2-hour TSA
treatment. Our iCLIP experiment has not enough sequencing
depth to perform a complete analysis on a single exon basis, but
we were able to extract a number of genes where the count
number in the I-E junctions was significant enough to analyze
changes between the libraries (see legend of Figure 5B and
Materials and Methods).
We analyzed the proportion of genes where the normalized I-E
count number was either increased or decreased by at least 2-fold
changed in any direction after TSA treatment. As a control for
changes in the non-specific binding of U2AF65 we used a similar
criterion to analyze E-I junctions. Figure 5B shows that while
nearly 20% of the genes show decreased U2AF65 binding at the I-
E junction in TSA 2 h, only 5% display increased binding, while
most of the genes show no change in any direction above the 2-
fold threshold. As a control, genes that change in the E-I junction
are not biased towards any direction, as expected from non-
specific binding that is not associated to the splicing process. As
indicated in the figure, the difference between the distributions is
statistically significant. This result indicates that even at an early
time (2 hours) the effect of TSA decreasing the efficiency of
splicing factor recruitment in a subset of genes can be detected,
although this decrease is still not visible when analyzing the bulk of
U2AF65 binding to 39ss.
Since 39 splice sites differ considerably between genes in
mammals, the fact that a fraction of the genes are more susceptible
to alterations in the chromatin structure is expected. Also,
genome-wide studies of nucleosome distribution showed that
exons flanked by longer introns and weak splice sites have a
stronger nucleosome positioning [39,42]. Based on this, we could
speculate that weak 39ss (for example those with shorter poly-
pyrimidine tracts) may need participation of chromatin assisted
recruitment mechanisms to enhance their recognition efficiency.
However, as previously mentioned, the sequencing depth of our
experiment precludes us to statistically analyze exon-by-exon to
undercover patterns of exon sensitivity to TSA.
The Speckle-localized Non-coding RNA MALAT1 Binds
U2AF65 Rapidly After TSA Treatment
As mentioned previously, RNA molecules participate in nuclear
compartmentalization, either with structural or regulatory roles.
Nuclear retained ncRNAs such as MALAT1 or NEAT1 bind
splicing factors and can regulate their localization and function. In
the case of speckles, MALAT1 is located in these granules and
modulates the localization of several splicing factors [25,26] and
their phosphorylation status [25]. MALAT1 seems to be
particularly abundant in neuronal cells, where it plays a role in
gene expression [26]. Also, the splicing factor TDP43 seems to be
sequestered by the ncRNAs MALAT1 and NEAT1 in the brain
cells of individuals with frontotemporal lobar degeneration, where
the level of these transcripts is augmented [55].
Since the only RNA sequence biotype that appeared over-
represented after TSA treatment in our iCLIP experiment was
long intergenic non-coding RNAs (lincRNAs), we asked whether
this could reflect binding of splicing factors to MALAT1. First, we
analyzed which lincRNAs showed increased binding after TSA
treatment. As seen in Fig. 5C, U2AF65 bound to MALAT1 and
NEAT1 explain almost completely the increase seen in total
binding to lincRNAs after 2 h and 6 h-TSA time points, with
NEAT1 having between 80–90% of all lincRNA counts. However,
the kinetics of U2AF65 binding to these ncRNAs is different: while
binding to MALAT1 increases at 2 h and then stays roughly at the
same level at 6 h of TSA (see inset), binding to NEAT1 only
increases modestly at 2 h but shows a pronounced increase in
binding at 6 h of TSA.
We next looked at the sites where U2AF65 binding to these
ncRNAs increases. Consistent with the variations in total counts,
new peaks (representing U2AF65 binding sites) appear in the case
of MALAT1 upon 2 h TSA treatment and either remain at the
same height, or are lost at the 6 h time point (Fig. 5D and Fig. S6,
top, orange boxes). The sequences correspond to short poly-
pyrimidine stretches, which likely are low-affinity U2AF65 binding
sites. In the case of NEAT1, the U2AF65 binding peaks increase
only partially at 2 h TSA and are significantly higher at 6 h
(Fig. 5D and Fig. S5, bottom, green boxes), consistent with what
we observed for total lincRNA counts (Fig. 5C).
Since MALAT1 binding of U2AF65 is correlated with
concentration of splicing factors in speckles, this re-localization
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could be explained by either an increase in speckle localization or
in total levels of this ncRNA. First, we analyzed the localization of
MALAT1 ncRNA in untreated or TSA treated cells using
fluorescence in situ hybridization (RNA-FISH). After 2 hours of
TSA treatment, when the increase in binding of U2AF65 is
detected by iCLIP, MALAT1 speckle-distribution remained
comparable to that of control cells (Fig. S7), arguing against a
causative role of MALAT1 in splicing factor localization. At 6 h
time point, MALAT1 showed a decreased localization in speckles
(Fig. S7). This MALAT1 reorganization also observed after
transcription inhibition [26], suggesting that it is secondary to
the accumulation of splicing factors in speckles, since Figures 2C
Figure 5. Chromatin relaxation affects spliceosome recruitment to nascent RNA and binding of splicing factors to ncRNAs. Binding of
U2AF65 to RNA was assessed by iCLIP in 293-Flp cells, as a measure of spliceosome recruitment in Control cells or cells treated with 1 mM TSA for 2 h
(before splicing factor accumulation in speckles is apparent) and 6 h. (A) TSA treatment causes an impairment of U2AF65 recruitment to the 39 splice
sites. Total U2AF65 counts in exon-intron (E-I) and intron-exon (I-E) junctions for all transcripts are plotted in a window of +/250 nt from the
junctions. The graph shows that iCLIP consistently captures U2AF65 at the expected location on the 39 splice site (I-E junction), where only non-
specific binding is detected at the E-I junction. The curve for 6 h TSA treatment (green) shows a reduction with respect to the control (blue) and 2 h
TSA treatment (red). (B) A fraction of the genes show sensitivity to TSA treatment at 2 hours. Each junction was analyzed separately, and for each
junction genes included in the analysis (see Materials and Methods) were divided into categories of increased (Up), decreased (Down) or unchanged
(less than 2-fold change in any direction) U2AF65 counts in a region of +/2100 nt around the corresponding junction. E-I junction was used as a
control, assuming that variations in these counts (non-specific) were random. Analysis of changes in the junctions of individual genes after 2 h TSA
treatment shows that almost 20% of the genes tend to have less U2AF65 binding in I-E junctions (and only 5% have increased binding). As a control,
E-I junction shows less than 10% of the genes with decreased binding and 7% with increased binding. Distributions for the two junctions are
significantly different (asterisk, chi-squared test for independence between fold-change categories and type of junction, p= 0.00032). (C) U2AF65
binding to lincRNAs increase upon TSA treatment. Distribution of lincRNA iCLIP counts in the three libraries, discriminating by the abundant MALAT1
and NEAT1 nuclear-retained ncRNAs and all the other lincRNAs. Inset: magnification of the binding to MALAT1 and other lincRNAs, excluding NEAT1.
(D) U2AF65 increase binding to specific sites in MALAT1 and NEAT1. UCSC browser window showing a portion of MALAT1 (top) and NEAT1 (bottom)
genes and the U2AF65 iCLIP counts for Control, 2 h and 6 h TSA-treated cells (complete genes with binding sequence info can be found in Fig. S5).
Orange boxes mark regions with peaks appearing at 2 h TSA and not further increasing, or even decreasing, at 6 h (MALAT1 peaks). Green boxes
mark regions with peaks gradually increasing to their maximum at 6 h TSA (NEAT1 peaks). (E) Co-immunofluorescence analysis on untreated HEK-293
cells (top row) and cells treated with 1 mM TSA for 2 h (middle) or 6 h (bottom). For each condition, a high magnification view of speckle and
paraspeckle compartments is shown (right panels). In untreated cells, the paraspeckles marker PSP1 does not colocalize with U2AF65 speckles, but
after 6 h TSA co-localization of PSP1 and U2AF65 is observed. 2 h TSA treatment leads to an intermediate state were paraspeckles and U2AF65
granules are starting to be associated. Nuclei were stained with DAPI. Scale bars, 10 mm.
doi:10.1371/journal.pone.0048084.g005
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and S1 clearly show that TSA causes no inhibition of general
transcription. In addition, we analyzed the steady state levels of
this ncRNA in HeLa cells treated with TSA for 6 hours, using
quantitative RT-PCR. We observed that MALAT1 levels were not
affected by the treatment (Fig. S8, left). These experiments
strongly suggest that changes in MALAT1 are not the cause of
splicing factor re-localization, supporting the notion that this
ncRNA mainly acts as a buffer of free splicing factors in the
nucleus.
In contrast to MALAT1, NEAT1 steady state levels increase
around 50% (Fig. S8, right) after 6 h TSA treatment. Therefore,
augmented levels of NEAT1 after TSA treatment could explain
the observed increase of NEAT1-bound U2AF65, which is also
seen at the 6-hour time point. Since this ncRNA is a structural
component of paraspeckles [24], we investigated the possibility of a
stronger association of U2AF65 with these particular nuclear
bodies. Interestingly, co-immunostaining of endogenous U2AF65
and the paraspeckle protein PSP1 [56] in HEK-293 cells show
that, while U2AF65 was not co-localized with paraspeckles in
control cells, after 6 hours of TSA treatment the paraspeckles
greatly increased their association to U2AF65 speckles (Fig. 5E, see
also magnifications at the right). At 2 hour time point, the
association was partial and weaker (Fig. 5E). The same observation
was done in HeLa cells (Fig. S9).
In summary, while these results support a direct relationship
between splicing factor re-localization and binding to MALAT1,
they strongly suggest that the accumulation of splicing factors in
the granular compartment is not due to increased presence of
MALAT1 in nuclear speckles. Since the total levels of MALAT1
remain similar after TSA, the appearance of new U2AF65 binding
events on low affinity sites should be related to the re-localization
of U2AF65 from the nucleoplasm to speckles and can be
interpreted as a buffering interaction that deals with the excess
of free U2AF65. Whether the presence of such sites accounts for
the capacity of speckles to accommodate the excess of splicing
factors remains to be explored for this and other splicing factors. In
the case of NEAT1, an increase in expression levels could account
for more U2AF65 binding after 6 h TSA treatment. This suggests
an alternative mechanism to the model presented in Fig. 4D to
explain the re-distribution of splicing factors, in this case from
nucleoplasm to paraspeckles. However, this association with
paraspeckles involved a minor fraction of U2AF65 (Fig. 5E and
Fig. S9), suggesting that most of the splicing factor concentration
in speckles is not related to the increase in expression of NEAT1
and the association with paraspeckles. Of course, it doesn’t exclude
the possibility that both mechanisms are acting together and that,
for example, the decrease of U2AF65 binding to the bulk of 39
splice sites at 6 h (Fig. 5A) could be mediated in part by
sequestration of U2AF65 by NEAT1.
Conclusions
It has been known for some time that HDAC inhibitors can
affect alternative splicing choices, since the first report of TSA
counteracting the effect of plasmid replication on alternative
splicing of a fibronectin exon reporter [34]. In the light of further
mechanistic studies that demonstrated that slower pol II elonga-
tion favors recognition of weak exons [57], this result was
interpreted as an effect of chromatin structure on pol II
processivity: relaxation of chromatin prevents pol II to pause,
giving less time for efficient co-transcriptional recognition of weak
splice sites. Further evidence was presented for this model in
endogenous genes [32,33,35].
We should remark that although changes in chromatin structure
were shown to affect alternative splicing by promoting separate
changes in pol II elongation and splicing factor recruitment, both
mechanisms can be considered together in a single model for co-
transcriptional regulation of alternative splicing. In fact, it is
completely plausible that the changes in pol II elongation
determine the efficiency of splicing factor recruitment to specific
RNA elements, in particular if recruitment is mediated by the
transcriptional machinery. An important part of this hypothesis is
that recruitment of splicing factors is, at least for some events,
inefficient and can be helped by pol II pausing. In a previous study
with the HDAC inhibitor sodium butyrate, where splicing
microarray analysis was used to uncover ,700 genes with
alternative splicing events sensitive to histone acetylation, it was
shown that the treatment can affect the recruitment of the SR
protein SRSF5 (previously known as SRp40) to one of the
responsive exons [58]. However, the example was limited to a
single protein in a single pre-mRNA species, which prevented
generalization of the mechanism.
Here, we present evidence that chromatin relaxation affects the
distribution of multiple splicing factors. By using a range of
imaging approaches, we demonstrate that this effect likely reflects
a decrease in the association of splicing factors with RNA, which
can affect spliceosome recruitment in a subset of exons. Why some
exons are particularly sensitive to chromatin perturbation remains
to be resolved, although this is consistent with results showing that
only a small fraction of the alternatively spliced genes assayed for
sensitivity to sodium butyrate was in fact affected by the treatment
[58]. It seems that some splicing events have a stronger need for
chromatin assistance than others. The mechanistic reasons for this
await further molecular analysis of the dynamic interactions
between splicing factors and specific RNA substrates.
Materials and Methods
Plasmids
Plasmids expressing fluorescent fusion proteins were based on
EGFP-C1, EYFP-C1 (Clontech Laboratories, Inc) or mCherry-C1
[59] expression vectors. Plasmids expressing mCherry-H2B [45],
EGFP-U1 70K, mCherry-SRSF1, EYFP-SRSF3 [51], EGFP-
U1A [60], T7-SRSF1 and T7-SRSF2 proteins were previously
described [61]. EGFP-SRSF1 is a generous gift from G. Biamonti
(Istituto di Genetica Molecolare (IGM-CNR). EGFP-SRSF2
construct was generated by subcloning SRSF2 fragment from
mCherry-SRSF2 as described previously [48]. EGFP-U2AF65
construct was generated by EcoR1/BamH1 digestion and gel
extraction from EYFP-U2AF65 [62] and ligation into pEGFP-C1.
pSV2-mMALAT1 [25] construct was a kind gift from Dr. KV.
Prasanth, University of Illinois at Urbana-Champaign, USA.
Cell Culture, Treatments and Transfections
HeLa, HEK-293T and N2a cells were cultured in DMEM
(Invitrogen) supplemented with 10% FBS and 100 U/ml penicil-
lin/streptomycin. The stable HeLa cell line expressing histone
H2B-EGFP [45] was cultured in DME supplemented with 10%
FBS, 100 U/ml penicillin/streptomycin, and 2 mg/ml blasticidin-
S. TSA (Sigma-Aldrich) was added to the cells at a final
concentration of 0.2 ng/ml for 6 hours, or otherwise indicated.
Depolarization treatment of N2a cells consisted in supplementing
the culture medium with 60 mM KCl for 6 hours. Cells were
treated with 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole
(DRB) at 25mg/ml for 2 h. For actinomycin D (ActD) treatment,
cells were incubated with 1 mg/ml ActD for 2 h.
C33A cells were grown in 6 well dishes and transfected with
EYFP-U2AF65 and EYFP-SRSF1 constructs following Effectene
transfection reagent instructions (Qiagen). 24 hours after trans-
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fection, cells were put under selection with G418 at 200 mg/ml in
DMEM supplemented with 10% FCS. After 3–4 weeks of
selection, resistant colonies were picked and screened for
expression of the fluorescently tagged proteins. Clones showing
acceptable levels of expression were picked and seeded into 24 well
dishes and grown under selection for a further 2 weeks. The clones
were screened by fluorescence microscopy and colonies showing
expression of the tagged proteins in all cells were expanded as cell
lines.
When indicated, cells were transfected with 1 mg/90-mm dish of
the appropriate plasmid DNA using Effectene (QIAGEN)
transfection reagent (HeLa) or Lipofectamine 2000 (Invitrogen)
reagent (N2a and HEK-293T) according to the manufacturer’s
instructions. For siRNA transfections in HeLa cells, the RNAi-
MAX reagent (Invitrogen) was used. siRNA against HP1a, a kind
gift from Dr. Alexia Ferrand (Wellcome Trust Biocentre, Dundee),
was previously described [63].
C33A and N2a cells were originally obtained from ATCC.
Imaging of Fixed and Living Cells
For imaging on fixed cells, cells were grown on glass coverslips
and fixed for 5 min in 3.7% paraformaldehyde in 37uC PHEM
buffer (60 mM Pipes, 25 mM Hepes, 10 mM EGTA, and 2 mM
MgCl2, pH 6.9). After a 10-min permeabilization with 1% Triton
X-100 in PBS, cells were blocked with 1% goat serum for 30 min
and then incubated with primary antibodies for 1 h, washed, and
incubated with secondary antibodies for 45 min. If required, cells
were stained with 0.3 mg/ml DAPI (Sigma-Aldrich). After a final
set of washes, cells were mounted in Vectashield media (Vector
Laboratories). Primary antibodies: anti-SRSF1 (S4045, Sigma)
antibody was used 1:1000, anti–HP1a (Euromedex) was used
1:500, anti-U2AF65 (mAb MC3, Sigma) was used 1:100 and anti-
PSP1 [56] was used 1:1000. anti-H3K36me3 (abcam 9050) was
used at 1:500.
For live imaging of FP-fused proteins, cells were cultured in
glass-bottomed dishes (WILCO; Intracel). Before imaging, growth
medium was replaced with phenol red–free CO2-independent
medium (Invitrogen).
Immunofluorescence images were acquired with a wide-field
fluorescence microscope (DeltaVision Spectris; Applied Precision)
and a CoolMax charge-coupled device camera (Roper Industries).
Imaging was performed at room temperature using a 606 oil
immersion NA 1.4 Plan-Apochromat objective from Olympus.
SoftWoRx software (Applied Precision) was used for image
acquisition. We used a deconvolution cluster (Spinlock) for offline
deconvolution of data. For co-localization and FISH experiments,
fluorescence images were acquired using a laser scanning confocal
microscope LSM780 from Zeiss (6361.4 NA oil Plan-Apochromat
objective, Zeiss). Z-series of 0.4 mm slices spanning the entire
nuclei were recorded. ImageJ software was used for image analysis.
5-FU Incorporation Assay
HeLa cells, either mock treated or ATP depleted for 30 min or
after washing and recovery for 30 min, were incubated with 2 mM
5-FU (Sigma-Aldrich) for 30 min at 37uC. Subsequently, cells
were fixed, permeabilized, and incubated with primary anti-BrdU
antibody (1:500; Sigma-Aldrich). Immunofluorescence microscopy
was performed as indicated in the previous section. Mean intensity
values were used for quantification and analysis.
Quantification of Speckles Intensity
We measured the splicing factor presence in speckles for EGFP-
SFSR1 and 2 (Fig. 1C) and endogenous SFSR2 (Fig. S3B).
Quantification of the fluorescence signal in single cells was
performed after acquisition, using ImageJ software. The focal
plane used for quantification was selected by comparing the mean,
standard deviation and maximum values of the stack and selecting
the highest. Speckles were selected using Maximum Entropy
threshold, and then the integrated density of all speckles was
calculated using particle analysis. For correcting for cell-to-cell
variations in size or signal intensity, speckles values were
normalized to the total integrated density of that cell.
Quantification of Total Endogenous SRSF2 and SRSF2
Nucleoplasmic Fraction
Quantification of the fluorescence signal in single cells was
performed after acquisition, using ImageJ software. Since several
focal (z) planes were acquired for each field, the first step when
analyzing a single cell was to measure the mean intensity of anti-
SRSF2 fluorescence in all z planes to find the maximum value, to
be sure that in each cell the image used has a well-focused nucleus.
In that z plane, we used ImageJ Default threshold option to select
the nucleus keeping the areas with background fluorescence out of
the calculation. This threshold value was named A. The integrated
density value applying this threshold corresponded to total SRSF2
signal. By measuring DAPI signal in the same z plane, we can
quantify total SRSF2 signal relative to DAPI signal. Then, we used
ImageJ Maximum Entropy threshold option, which resulted in
selection of the high signal intensity areas of the images, in this
case, the speckles. This threshold value was named B. Finally,
using A and B values to manually adjust down and up thresholds,
we calculated the intermediate SRSF2 signal, which corresponded
to nucleoplasmic signal. The nucleoplasmic fraction was calculated
by dividing nucleoplasmic/total SRSF2 signal ((A-B)/B).
Structured Illumination Protocol for Image Acquisitions
The protocol was as described previously [64]. 3DSIM was
performed on a microscope system OMX version 2 (Applied
Precision, Issaquah, WA) equipped with 405, 488, and 593 and
642 nm solid-state lasers. Images were acquired using a UPlanS
Apochromat 10061.4 NA oil immersion objective lens and back-
illuminated 5126512 electron microscopy charge-coupled device
cameras (Cascade II; Photometrics). Samples were illuminated by
a coherent scrambled laser light source that had passed through a
diffraction grating, thus generating interference of light orders in
the image plane to create a 3D sinusoidal pattern with lateral
stripes ,0.2 mm apart. The pattern was shifted laterally through
five phases and three angular rotations of 60u for each z section.
Optical sections were separated by 0.125 mm. Exposure times
were between 200 and 500 ms, and the laser power was adjusted
to achieve optimal intensities between 2000 and 4000 counts in a
raw image of 16-bit dynamic range at the lowest laser power
possible to minimize photobleaching. Each frame acquisition was
separated by a 300-ms pause. Multichannel imaging was achieved
through sequential acquisition of wavelengths by separate cam-
eras. Raw 3DSIM images were processed and reconstructed to
reveal structures with greater resolution [65]. The channels were
aligned in x, y and rotationally by using predetermined shifts as
measured using a target lens and the SoftwoRx alignment tool
(Applied Precision). After correction for image shifts due to
differences in emission wavelengths, data sets were transferred to
SoftWoRx software (Applied Precision) for visualization and
generation of xz plane images.
Fluorescence Recovery After Photobleaching (FRAP)
C33A stable cell lines or HeLa cells were directly cultured or
transiently transfected in glass-bottomed dishes (WILCO; Intra-
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cel), respectively. Before imaging, growth medium was replaced
with phenol-red free CO2- independent medium (Invitrogen).
Cells expressing FP-fusion proteins were imaged using Olympus
U-Plan-Apo 10061.35NA objective and photobleached by using
the ‘‘photokinetic experiment’’ function of the DeltaVision
Spectris microscope. Briefly, a small region inside nucleus was
photobleached with a 488 nm laser (100% laser power for the
duration of 0.15 s), and time-lapse sequences of single optical
sections for imaging FP-fluorescence were collected with an
exposure time of 0.05 s for each image. The fluorescence
intensities in the bleached and non-bleached area before (three
time points) and after laser photobleaching were quantified using
ImageJ software.
Fluorescence Lifetime Imaging Microscopy
FLIM–FRET measurements were acquired and analyzed as
described previously [50,51]. Briefly, FRET measurements by
FLIM were performed on a confocal laser-scanning microscope
(Radiance 2100 MP; Bio-Rad Laboratories) on a stand (TE2000;
Nikon) using a 606/1.4 NA Plan Apo oil immersion lens (Nikon)
equipped with a titanium sapphire laser (Chameleon from
Coherent) providing femtosecond pulses at a 90-MHz repetition
rate. Light shielding and environmental control were achieved
using a black environmental chamber that surrounded the
microscope stage and stand (Solent Scientific) maintaining cells
at 37uC and limiting stray light from entering the detectors.
Presence of both EGFP and mCherry signals was confirmed using
the confocal light path with the 488-nm argon ion and 543-nm
HeNe laser lines. Two photon excitation for FLIM was performed
at 890 nm with a 600 fps scan speed at 5126512 resolution for
90–120 s, and fluorescent light was collected on a nondescanned
detector (5783P; Hamamatsu Photonics) using a 670-nm long-pass
dichroic mirror and a 528/50-nm band-pass emission filter, such
that only GFP was excited and collected. Time correlated single
photon counting was performed using a photon-counting card
(SPC830; Becker & Hickl), and subsequent analysis was performed
with SPCImage (Becker & Hickl).
Because FRET interactions cause a decrease in the fluorescence
lifetime of the donor molecules (EGFP), the FRET efficiency can
be calculated by comparing the FLIM values obtained for the
EGFP donor fluorophores in the presence and absence of the
mCherry acceptor fluorophores (Fig. 4 B and Fig. 4C). Mean
FRET efficiency images were calculated such as the FRET
efficiency, EFRET= 1 - (tDA/tD), where t DA is the mean
fluorescence lifetime of the donor (H2B-EGFP or EGFP-U1 70K)
in the presence of the acceptor (mCherry-SRF1) and tD is the
mean fluorescence lifetime of the donor (H2B-EGFP EGFP-U1
70K) expressed in the presence of mCherry-C1 acceptor for all of
the cells imaged. In the non-FRET conditions, the mean
fluorescence lifetime value of the donor in the absence of the
acceptor was calculated from a mean of the tD by applying a
monoexponential decay model to fit the fluorescence lifetime
decays. Then, in the FRET conditions, we applied a biexponential
fluorescence decay model to fit the experimental decay. We
obtained information about the lifetime of two populations of
molecules, i.e., the noninteracting donor population tD and the
donor population that was interacting with the acceptor (tDA) as
well as the intensity factors a and b of the two decay components.
By fixing the noninteracting proteins lifetime tD using data from
control experiments (in the absence of FRET), the value of tDA
was estimated. Then, by knowing both values tDA and tD at each
single pixel, the FRET efficiency (EFRET) was derived by applying
the following equation: EFRET= 1 - (tDA/tD) at each pixel in a
selected ROI using SPCImage software. Furthermore, the FRET
distribution curves (Fig. 4 B, bottom panel) from these ROIs were
displayed from the extracted associated matrix using SPCImage
software.
RNA Fluorescence in Situ Hybridization (RNA-FISH)
To detect MALAT1 RNA, HeLa cells were grown on glass
coverslips, rinsed briefly with PBS and fixed in 4% formaldehyde
in PBS for 15 min at RT. Then, cells were permeabilized in PBS
containing 0.5% Triton X-100 and 5 mM vanadyl-ribonucleoside
complex (VRC, Sigma) on ice for 10 min; washed with PBS
3610 min and rinsed once in 26SSC prior to hybridization.
Hybridization was carried out using nick-translated full-length
mMALAT1 cDNA probe (Abbott Molecular, USA) in a moist
chamber at 37uC overnight as described elsewhere [25]. Fluores-
cence images were acquired as described above.
SR Protein Acetylation Assay
HEK-293T cells transfected with T7-SRSF1, T7-SRSF2 or
empty vector were lysed in 293 IP Buffer (20 mM Tris PH=7.5,
150 mM KCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA).
Lysates were clarified 109 at 12.000 RPM. Immunoprecipitation
was performed overnight with T7 tag antibody-agarose (Novagen),
washed 3 times and resuspended in Laemmli Buffer. Western blot
was done against anti-T7 tag monoclonal antibody (1:10000,
Novagen) or anti-acetylated lysine antibody (1:1000, Cell Signal-
ling). Histones were extracted from cells and western blot with
anti-total H3 antibody (Upstate, Millipore) was performed as in
[35]. Where mentioned, 10 mM MG132 (Sigma) was used.
U2AF65 iCLIP Analysis
iCLIP experiment was performed as previously described [54].
We used a HEK-293T cell line harboring a FRT site (Flp-in 293,
Invitrogen). We prepared libraries from three samples: non-treated
cells (control), cells treated with 1 mM trichostatin A for 2 hours
(TSA 2 h) or 6 hours (TSA 6 h). For immunoprecipitation, 7 ml of
monoclonal anti-U2AF65 antibody (U4758, Sigma) was used for
each sample. A no-antibody sample was also included. iCLIP data
analysis was carried on through the iCount pipeline by the Blaz
Zupan lab in the University of Ljubljana (http://icount.biolab.si).
For analysis of the proportion of genes with change of U2AF65
binding in exon-intron (E-I) or intron-exon (I-E) junctions after 2-
hour TSA treatment, a list of genes was made for each junction
(including +/2100 nt from the proper junction) containing the
genes with count number above threshold for at least one library.
Since TSA 2 h library was approximately 5-fold larger than
Control library, the threshold was set in 10 counts for Control and
50 counts for TSA 2 h. 742 genes were included in the I-E
junction group and 600 genes in the E-I junction group. The
number of counts per gene in each library was normalized using
the total number of counts in the same library. Then, we excluded
genes from the two groups that showed more than 2-fold change in
normalized total counts in the whole gene (not restricted to
junctions), assuming that the change in total counts evidenced that
mRNA levels of these genes were affected by the TSA treatment,
making interpretation of the variations difficult. After filtering out
these genes 565 genes were included in the I-E group and 461 in
the E-I group. The E-I group, of comparable size than the I-E
group, was used as a control for non-specific U2AF65 binding
variations, since Fig. 5A shows that counts are not associated to
any region of the junction but rather homogenously distributed.
Genes of the two groups were categorized as Up (if normalized
junction counts were at least 2-fold higher in TSA 2 h than in
Control library), Down (same but lower in TSA 2 h than in
Control library) and No Change (less than 2-fold change in the
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normalized junction counts between TSA 2 h and Control
libraries). For statistical evaluation, we used chi-squared test for
independence, considering the Up-Down-No Change categories
as a variable and the type of junction (E-I or I-E) as the other. The
null hypothesis was that the distribution of genes in the categories
Up-Down-No Change was independent from the type of junction.
To reject this hypothesis would imply that U2AF65 binding to the
I-E junctions (splicing associated binding) responds differently to
TSA than to the E-I junctions (non-specific binding).
Measurement of lincRNAs Levels
Total RNA extraction from cells, retrotranscription and real
time PCR was performed as previously described, including
amplification of the HSPCB housekeeping gene mRNA [35],
except that random decamers were used for RT instead of oligo-
dT primer. Sequence primers for MALAT1 and NEAT1
amplification was obtained from [25].
Supporting Information
Figure S1 No alteration of H3K36me3 after TSA treat-
ment. Immunostaining experiments using antibody against
histone H3 lysine 36 (H3K36me3), a hallmark of pol II
transcriptional elongation, on HeLa cells untreated or treated
with TSA 2 h and 6 h. A statistical quantification of anti-
H3K36me3 fluorescence intensity is shown. No changes were
observed after TSA treatment. Nuclei were counter-stained with
DAPI. Scale bars, 10 mm.
(TIFF)
Figure S2 Endogenous SRSF2 accumulates in speckles
after TSA treatment. Analysis of intensity profile of endoge-
nous SRSF2 and H3 levels signals across a line (yellow dotted lines)
for representative control and TSA-treated HeLa cells. SRSF2
profile shows lower basal intensity and higher peaks in TSA-
treated cells, corresponding to depletion of SRSF2 from
nucleoplasm and accumulation in speckles. No changes are seen
for H3 profiles. The wide valley of H3 signal in the TSA-treated
cell profile corresponds to the presence of a nucleolus.
(TIF)
Figure S3 Assessment of HP1a knockdown efficiency in
HeLa cells. HP1a protein was detected by immunofluorescence
with a specific antibody in cells transfected with either a control
siRNA or a siRNA targeting HP1a mRNA. DAPI staining of the
same field is shown to observe the cell nuclei. Scale bar, 10 mm.
(TIF)
Figure S4 Knockdown of HP1a causes a similar effect
on endogenous SRSF2 distribution as TSA treatment. (A)
SRSF2 localization after HP1a knockdown. HeLa cells were
transfected with control or HP1a-specific siRNAs. After three
days, they were fixed and immunostained for endogenous SRSF2
detection. DAPI staining is also shown. Cells transfected with
HP1a siRNA show less nucleoplasmic staining and more intense
speckles than control cells. For each sample, a representative cell
and the analysis of intensity profile of endogenous SRSF2 across
the indicated line are shown. (B) Statistical analysis of endogenous
SRSF2 enrichment in speckles after HP1a depletion. Signal of
SRSF2 in speckles increases in siHP1a transfected cells vs. cells
transfected with control siRNA. Intensity of splicing factor in all
speckles of a focal plane was calculated for individual cells using
automatic threshold and particle analysis (see Materials and
Methods). The total integrated density of speckles particles was
normalized by total integrated density of the cell. n=21 and 27 for
siControl and siHP1 respectively. * means significant differences
between treated and control cells, using Mann-Whitney U test
(p = 0.0021) or Kolmogov-Smirnov test (p = 0.022).
(TIF)
Figure S5 Comparison between the iCLIP libraries. (A)
Distribution of cDNA counts between the different types of
sequences in the Control, TSA 2 h and TSA 6 h libraries. 3UTR:
39 untranslated regions; 5UTR: 59 untranslated regions; ORF:
open reading frames; inter: intergenic regions; intron: intronic
regions; ncRNA: non-coding RNAs; telo: telomeric sequences; as:
counts mapped to anti-sense sequences. (B) Distribution of cDNA
counts among sequences biotypes. The only clear tendency is the
increase in ‘‘ncRNA, lincRNA’’ category (orange box) upon TSA
treatment.
(TIF)
Figure S6 U2AF65 binding sites on MALAT1 and NEAT1
ncRNAs. UCSC browser window showing the complete
MALAT1 (top) and NEAT1 (bottom) genes and the U2AF65
iCLIP counts for Control, 2 h and 6 h TSA-treated cells. As in
Fig. 5D, orange boxes mark regions with peaks appearing at 2 h
TSA and not further increasing, or even decreasing, at 6 h
(MALAT1 peaks). Green boxes mark regions with peaks gradually
increasing to their maximum at 6 h TSA (NEAT1 peaks). For all
the boxed peaks, the corresponding sequence is shown, with an
arrowhead pointing to the binding nucleotide.
(TIF)
Figure S7 Changes in MALAT1 localization upon TSA
treatment are not correlated with changes in splicing
factor localization or binding. RNA FISH using mMALAT1
probe in control untreated or 1 mM TSA-treated HeLa cells.
MALAT1, as expected, shows a speckled pattern in control HeLa
cells. A 2 h TSA treatment does not lead to any visible change in
this pattern, while at this time U2AF65 binding to MALAT1
increases (Fig. 5C). Moreover, a 6 h treatment results in partial re-
distribution of MALAT1 ncRNA from nuclear speckles to
nucleoplasm, while at this time-point the splicing factors are
concentrated in speckles (Fig. 2A and D; Fig. 3A). These
observations suggest that MALAT1 is not causing the re-
distribution of splicing factors in the nucleus. Note that weak
levels of MALAT1 can still be observed in some nuclear speckles.
DNA is counterstained with DAPI in blue. Right panels show
higher magnifications of individual nuclei. Scale bar, 10 mm.
(TIF)
Figure S8 NEAT1 but not MALAT1 RNA levels are
affected by TSA treatment. Total RNA was extracted from
HeLa cells, either untreated or incubated with 1 mM TSA for 6
hours. Steady-state levels of MALAT1 and NEAT1 ncRNAs were
analyzed by RT followed by quantitative real time PCR. The
MALAT1 and NEAT1 levels are relativized to the mRNA levels
of the housekeeping gene HSPCB. No differences were found
between the two samples for MALAT1, while a significant
increase is detected in TSA samples for NEAT1 (Student’s t test,
p=0.926 for MALAT1 and p=0.0176 for NEAT1, marked by
asterisk).
(TIF)
Figure S9 Gradual increase in U2AF65 splicing factor
and paraspeckles colocalization after TSA treatment in
HeLa cells. Same as Fig. 5E, but for HeLa cells. Co-
immunofluorescence of HeLa control cells (top row) and cells
treated 1 mM TSA for 2 h (middle) or 6 h (bottom). For each
condition, a high magnification view of speckle and paraspeckle
compartments is shown (right panels). In untreated cells, the
paraspeckles marker does not colocalize with U2AF65 speckles
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but, after 6 h TSA, co-localization of PSP1 and U2AF65 is
observed. 2 h TSA treatment leads to an intermediate state were
paraspeckles and U2AF65 are starting to be associated. Nuclei
were stained with DAPI. Scale bars, 10 mm.
(TIF)
Movie S1 3D reconstruction of individual speckles in
control cells using the SIM/OMX high-resolution mi-
croscopy system (see also Figure 3D in the main article).
(MPG)
Movie S2 3D reconstruction of individual speckles in
TSA-treated cells using the SIM/OMX high-resolution
microscopy system (see also Figure 3D in the main
article).
(MPG)
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